ENLV Logo

Enlivex Therapeutics Ltd (ENLV) Stock Forecast & Price Prediction

Live ENLV Stock Price & Analysis

Home โ€บ Stocks โ€บ Israel | NASDAQ | Healthcare | Biotechnology

$1.09

-0.01 (-0.91%)

12 Month Price Forecast For ENLV

$1.09
Current Price
$24.19M
Market Cap
2 Ratings
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to ENLV Price Forecasts

+1,092.7%
To High Target of $13.00
+771.6%
To Median Target of $9.50
+450.5%
To Low Target of $6.00

ENLV Price Momentum

+0.9%
1 Week Change
-4.4%
1 Month Change
-61.1%
1 Year Change
-6.8%
Year-to-Date Change
-76.3%
From 52W High of $4.59
+34.6%
From 52W Low of $0.81

๐Ÿค” Considering Enlivex (ENLV)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 9:45 PM UTC

ENLV Analyst Ratings & Price Targets

Based on our analysis of 3 Wall Street analysts, ENLV has a bullish consensus with a median price target of $9.50 (ranging from $6.00 to $13.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.09, the median forecast implies a 771.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,092.7% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 450.5% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ENLV Analyst Consensus

2
Buy
0
Hold
0
Sell

ENLV Price Target Range

Low
$6.00
Average
$9.50
High
$13.00
Current: $1.09

Latest ENLV Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ENLV.

Date Firm Analyst Rating Change Price Target
Feb 7, 2025 D. Boral Capital Jason Kolbert Buy Maintains $13.00
Dec 11, 2024 D. Boral Capital Jason Kolbert Buy Maintains $13.00
Dec 3, 2024 D. Boral Capital Jason Kolbert Buy Maintains $13.00
Nov 14, 2024 D. Boral Capital Jason Kolbert Buy Maintains $13.00
Sep 27, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $6.00
Sep 26, 2024 EF Hutton Jason Kolbert Buy Maintains $13.00
Sep 24, 2024 EF Hutton Jason Kolbert Buy Maintains $13.00
Sep 9, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $6.00
Aug 27, 2024 EF Hutton Jason Kolbert Buy Initiates $13.00
Jun 11, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $6.00
Apr 23, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $7.00
Apr 12, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $7.00
Sep 25, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $12.00
Aug 1, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $15.00
Apr 24, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $15.00
Apr 5, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $15.00
Feb 24, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $15.00
May 2, 2022 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $15.00
Jan 9, 2020 H.C. Wainwright Buy Initiates $0.00
Jan 9, 2020 HC Wainwright & Co. Buy Initiates $0.00

Stocks Similar to Enlivex Therapeutics Ltd

The following stocks are similar to Enlivex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Enlivex Therapeutics Ltd (ENLV) Financial Data

Enlivex Therapeutics Ltd has a market capitalization of $24.19M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -61.2%.

Valuation Metrics

Market Cap $24.19M
Enterprise Value $-1,300,024
P/E Ratio -0.7x
PEG Ratio -1.9x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +113.9%
Current Ratio 10.1x
Debt/Equity 2.9x
ROE -61.2%
ROA -27.5%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Enlivex Therapeutics Ltd logo

Enlivex Therapeutics Ltd (ENLV) Company Overview

About Enlivex Therapeutics Ltd

What They Do

Develops immunotherapy for organ dysfunction and osteoarthritis.

Business Model

The company operates as a clinical-stage entity focused on macrophage reprogramming immunotherapy, primarily generating revenue through the development and eventual commercialization of its lead product, Allocetra. It is currently in various phases of clinical trials targeting conditions like sepsis and knee osteoarthritis, aiming to secure partnerships or licensing agreements to monetize its innovations.

Additional Information

Enlivex Therapeutics is based in Ness Ziona, Israel, and is actively pursuing treatments that address significant unmet medical needs, which may enhance its market potential and attract investment as clinical trials progress.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

0

CEO

Country

Israel

IPO Year

N/A

Enlivex Therapeutics Ltd (ENLV) Latest News & Analysis

ENLV stock latest news image
Quick Summary

RedChip Companies will feature interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on Bloomberg TV's RedChip show on January 11 at 7 p.m.

Why It Matters

The interviews could boost visibility and interest in Enlivex and bioAffinity, potentially impacting their stock performance and attracting new investors.

Source: Accesswire
Market Sentiment: Neutral
ENLV stock latest news image
Quick Summary

Enlivex Therapeutics has received Israeli Ministry of Health approval to start a Phase I trial for Allocetraโ„ข in TMJ osteoarthritis patients, focusing on safety and efficacy.

Why It Matters

The initiation of a Phase I trial for Allocetraโ„ข could signal potential advancements in treatment options, affecting Enlivex's stock performance and market perception in immunotherapy.

Source: GlobeNewsWire
Market Sentiment: Neutral
ENLV stock latest news image
Quick Summary

Enlivex Therapeutics (Nasdaq: ENLV) reported positive interim efficacy data from its Phase I/II Allocetraโ„ข trial for knee osteoarthritis.

Why It Matters

Positive interim results from Enlivex's trial could boost investor confidence, indicating potential for future market success and increased stock value in the biopharmaceutical sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
ENLV stock latest news image
Quick Summary

Enlivex Therapeutics Ltd. (Nasdaq:ENLV) will host a webinar for investors on December 3, 2024, at 11:00 a.m. regarding their macrophage reprogramming immunotherapy developments.

Why It Matters

The webinar announcement signals potential updates on Enlivex's clinical progress, which could influence stock performance and investor sentiment.

Source: Accesswire
Market Sentiment: Neutral
ENLV stock latest news image
Quick Summary

Enlivex Therapeutics has completed dosing for the first patient in its Phase I trial of Allocetraโ„ข for psoriatic arthritis, reporting no safety concerns.

Why It Matters

Completion of initial dosing in Enlivex's Phase I trial for Allocetraโ„ข indicates progress in drug development for psoriatic arthritis, potentially enhancing the company's valuation and investor confidence.

Source: GlobeNewsWire
Market Sentiment: Neutral
ENLV stock latest news image
Quick Summary

Enlivex Therapeutics announced the Japanese Patent Office will issue a patent for therapeutic apoptotic cells for osteoarthritis, providing IP protection until at least 2040.

Why It Matters

Enlivex's new patent for osteoarthritis treatment enhances its IP protection, potentially increasing its market value and competitive advantage, which may attract investor interest.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About ENLV Stock

What is Enlivex Therapeutics Ltd's (ENLV) stock forecast for 2025?

Based on our analysis of 3 Wall Street analysts, Enlivex Therapeutics Ltd (ENLV) has a median price target of $9.50. The highest price target is $13.00 and the lowest is $6.00.

Is ENLV stock a good investment in 2025?

According to current analyst ratings, ENLV has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.09. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ENLV stock?

Wall Street analysts predict ENLV stock could reach $9.50 in the next 12 months. This represents a 771.6% increase from the current price of $1.09. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Enlivex Therapeutics Ltd's business model?

The company operates as a clinical-stage entity focused on macrophage reprogramming immunotherapy, primarily generating revenue through the development and eventual commercialization of its lead product, Allocetra. It is currently in various phases of clinical trials targeting conditions like sepsis and knee osteoarthritis, aiming to secure partnerships or licensing agreements to monetize its innovations.

What is the highest forecasted price for ENLV Enlivex Therapeutics Ltd?

The highest price target for ENLV is $13.00 from Jason Kolbert at D. Boral Capital, which represents a 1,092.7% increase from the current price of $1.09.

What is the lowest forecasted price for ENLV Enlivex Therapeutics Ltd?

The lowest price target for ENLV is $6.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 450.5% increase from the current price of $1.09.

What is the overall ENLV consensus from analysts for Enlivex Therapeutics Ltd?

The overall analyst consensus for ENLV is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.50.

How accurate are ENLV stock price projections?

Stock price projections, including those for Enlivex Therapeutics Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.